Dr. Erin H Breese, MD, PhD
Claim this profileCincinnati Children's Hospital Medical Center
Area of expertise
Non-Hodgkin's Lymphoma
Erin H Breese, MD, PhD has run 13 trials for Non-Hodgkin's Lymphoma. Some of their research focus areas include:
Neuroblastoma
Erin H Breese, MD, PhD has run 11 trials for Neuroblastoma. Some of their research focus areas include:
Affiliated Hospitals
Cincinnati Children's Hospital Medical Center
Cincinnati Children's Hospital
Clinical Trials Erin H Breese, MD, PhD is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab ozogamicin is a monoclonal antibody, which is a type of protein that can bind to certain targets on the surface of cells. Inotuzumab ozogamicin is a monoclonal antibody that is linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells by binding to the CD22 protein on the surface of the cancer cell and delivering calicheamicin inside the cells to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Blinatumomab is a specialized type of monoclonal antibody known as a bispecific T-cell engager (BiTE). It works by simultaneously binding to CD19 on cancer cells and CD3 on normal immune cells, bringing them together to destroy leukemia cells. Blinatumomab is a standard part of chemo-immunotherapy treatment for B-ALL. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin or blinatumomab. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemo-immunotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first phase of therapy: Induction. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-induction treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (consolidation, blinatumomab block 1, interim maintenance 1, blinatumomab block 2, delayed intensification, interim maintenance 2, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of consolidation or part of delayed intensification. Other aims of this study include evaluating 1) side effects of treatment using patient-reported outcomes and health-related quality of life, 2) the best ways to help patients adhere to oral chemotherapy regimens, 3) the relationship between levels of inotuzumab ozogamicin in the blood and side effects, 4) the impact of chemo-immunotherapy on the immune system and risk of infection, and 5) the impact of social determinants of health on outcomes. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting
2 awards
Phase 3
Blinatumomab + Nivolumab
for Acute Lymphoblastic Leukemia
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.
Recruiting
1 award
Phase 2
8 criteria
More about Erin H Breese, MD, PhD
Clinical Trial Related
9 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Erin H Breese, MD, PhD has experience with
- Cyclophosphamide
- Prednisolone
- Methotrexate
- Pegaspargase
- Mercaptopurine
- Dexamethasone
Breakdown of trials Erin H Breese, MD, PhD has run
Non-Hodgkin's Lymphoma
Neuroblastoma
Langerhans Cell Histiocytosis
Diffuse Hemispheric Glioma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Erin H Breese, MD, PhD specialize in?
Erin H Breese, MD, PhD focuses on Non-Hodgkin's Lymphoma and Neuroblastoma. In particular, much of their work with Non-Hodgkin's Lymphoma has involved Stage I patients, or patients who are Stage II.
Is Erin H Breese, MD, PhD currently recruiting for clinical trials?
Yes, Erin H Breese, MD, PhD is currently recruiting for 2 clinical trials in Cincinnati Ohio. If you're interested in participating, you should apply.
Are there any treatments that Erin H Breese, MD, PhD has studied deeply?
Yes, Erin H Breese, MD, PhD has studied treatments such as Cyclophosphamide, Prednisolone, Methotrexate.
What is the best way to schedule an appointment with Erin H Breese, MD, PhD?
Apply for one of the trials that Erin H Breese, MD, PhD is conducting.
What is the office address of Erin H Breese, MD, PhD?
The office of Erin H Breese, MD, PhD is located at: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229 United States. This is the address for their practice at the Cincinnati Children's Hospital Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.